Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025
China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...
Clinical trial results
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...
AstraZeneca’s Breztri Aerosphere Meets Primary Endpoints in Phase III Asthma Trials
UK-based pharmaceutical firm AstraZeneca (AZ; NASDAQ: AZN) this week unveiled results from the Phase III...
Alphamab and CSPC Announce Positive Interim Results for KN026 in HER2+ Gastric Cancer Trial
China-based firms Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced top-line results from the Phase III ARISE trial...
Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib...
Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
China-based Akeso, Inc. (HKG: 9926) announced strongly positive results from the regulatory Phase III AK112-306/HARMONi-6...
Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated...
HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment for the...
Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes
U.S. pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has announced positive top-line results from...
Easton Pharma’s EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...
AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients
Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...
BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...
Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...
HighTide Therapeutics’ HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical...
Amgen’s Imdelltra Shows Positive Phase III Results in Small Cell Lung Cancer
US biotech giant Amgen (NASDAQ: AMGN) has announced positive results from the global Phase III...
CK Life Sciences Reports Promising Preclinical Results for TROP2-Targeted Cancer Vaccine
China-based CK Life Sciences (HKG: 0775) has announced positive early results from preclinical studies of...
SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...